HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Cohance Lifesciences Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 27, 2025

Key Highlights

  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1092 as of 27 May 15:30.
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 55.8 on March 2024 . This represents a CAGR of -24.43% over 5 years.
  • The Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 32917 crore on March 2024 . This represents a CAGR of 9.31% over 5 years.
  • The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the decline of -100% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 1015 crore as compare to the Dec '24 revenue of ₹ 984.49 crore. This represent the growth of 3.1%.
  • The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -100% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 373.87 crore as compare to the Dec '24 ebitda of ₹ 326.99 crore. This represent the growth of 14.34%.
  • The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 262.87 crore over 8 quarters. This represents a CAGR of 40.98% .
  • The Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 92.72 % on March 2024 . This represents a CAGR of -31.52% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
  • The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same per...

Read more

14 May 2025 12:47

News

GlaxoSmithKline Pharmaceuticals AGM scheduled

GlaxoSmithKline Pharmaceuticals announced that the Annual General Meeting(AGM) of the comp...

Read more

13 May 2025 17:18

News

Board of GlaxoSmithKline Pharmaceuticals recommends final dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

13 May 2025 17:18

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

News

GlaxoSmithKline Pharmaceuticals revises board meeting date

GlaxoSmithKline Pharmaceuticals has revised the meeting of the Board of Directors which wa...

Read more

21 Jan 2025 11:16

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Suven Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Suven Pharmaceuticals Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Suven Pharmaceuticals Ltd is 27,815 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 52,833 Cr

What are the key factors driving the stock performance of Suven Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Suven Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 27, 2025, the Suven Pharmaceuticals Ltd stock price is INR ₹1092.65. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹3118.75.

How do dividend payouts of Suven Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Suven Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions